

REMARKS

In response to the Action, Applicants hereby submit the following amendments to the specification, drawings and claims. No new matter is added by these amendments.

As a preliminary matter, Applicants hereby amend the sequence provided in Figure 2 for “Hu Colligin 2” from AVSLAEQLR to AVLSAEQLR, as shown in substitute Figure 2 and the annotated version thereof, both of which are provided herewith. The substitute sheet containing Figure 2, submitted by Applicants in the **Amendment and Response to Office Action** dated June 30, 2004 contained an inversion of two amino acids as compared to the as-filed sequence of human colligin 2. The original, as-filed version of that sequence was AVLSAEQLR, not AVSLAEQLR. Further, the last line of claim 51 is amended to remove the second iteration of “by.”

The Examiner has requested that Applicants amend the specification, drawings, claims and/or Sequence Listing of the present application in order to comply with the requirements of 37 CFR 1.821 *et seq.* In response, Applicants hereby amend the specification, drawing and claims of the present application. No amendments to the Sequence Listing of Computer Readable Form (CRF) are believed necessary to meet the sequence listing requirements. Claims 60, 63 and 80-292 are hereby amended to include a sequence identifier. References in the specification to Figures 2, 11 and 15 are hereby amended to include sequence identifiers. The sequence for Hu Colligin 2 provided in Figure 2 is hereby amended for reasons described above. No new Sequence Listing is required because that sequence is provided in SEQ ID NO: 3.

Applicants believe the claims define over the prior art of record and are in proper form for allowance. Applicants respectfully request allowance of claims 51 and 60-292.


Respectfully submitted,

A handwritten signature in black ink, appearing to read 'J. Hirshman', is written over a horizontal line.

Jesse A. Hirshman
Registration No. 40,016

Attorney for Applicants

KIRKPATRICK & LOCKHART LLP
Henry W. Oliver Building
535 Smithfield Street
Pittsburgh, Pennsylvania 15222-2312
Telephone: (415) 355-8966
Facsimile: (412) 355-6501
E-mail: jhirshman@kl.com



Alignment of HSP47 with HLA/IL-12 β Chains

<u>Molecule</u>	<u>Position</u>	<u>Amino Acid Sequence</u>	<u>Position</u>
Human Hsp47	96	AvlsAEQLR	104
Hu Colligin 2	95	AVLSAEQLR	103
HLA-A2 A*0201	149	AahvAEQLR	157
HLA-A2 A*0204	167	AahvAEQLR	175
HLA-A2 A*0206	175	AahvAEQLR	183
HLA-A2 A*0211	166	AahvAEQLR	174
HLA-A10 alpha	84	AahvAEQLR	92
HLA-Aw 69	150	AahvAEQLR	158
Rat Hsp47	94	AVLSAEkLR	102
Mouse Hsp47	94	AVLSAEkLR	102
Hamster Hsp47	94	AVLSAEkLR	102
Chicken Hsp47	82	AVLSAdkLn	90
Hu IL-12 β -chain	150	AtLSAErvR	158
Mouse IL-1 2 β -chain	150	AtLSAErvR	158
cat IL-12 β -chain	150	AtLSAEkvR	158
cow IL 12 β -chain	150	A1SAEkvn	158
Consensus HSP		AVLSA(d,e)(k,q)LR	
Consensus HLA		A(v,a)(l,h)(a,v)AEQLR	
Consensus IL-12 β -chain		A(v,l,t)LSAE(q,k,r)(l,v)R	
Overall Consensus		A(v,l,a,t)(l,h)(a,v)A(d,e)(k,q,r)(l,v)R	

FIG. 2



Alignment of HSP47 with HLA/IL-12 β Chains

<u>Molecule</u>	<u>Position</u>	<u>Amino Acid Sequence</u>	<u>Position</u>
Human Hsp47	96	AvlsAEQLR	104
Hu Colligin 2	95	AVSLAEQLR	103
HLA-A2 A*0201	149	AahvAEQLR	157
HLA-A2 A*0204	167	AahvAEQLR	175
HLA-A2 A*0206	175	AahvAEQLR	183
HLA-A2 A*0211	166	AahvAEQLR	174
HLA-A10 alpha	84	AahvAEQLR	92
HLA-Aw 69	150	AahvAEQLR	158
Rat Hsp47	94	AVLSAEkLR	102
Mouse Hsp47	94	AVLSAEkLR	102
Hamster Hsp47	94	AVLSAEkLR	102
Chicken Hsp47	82	AVLSAdkLn	90
Hu IL-12 β -chain	150	AtLSAErvR	158
Mouse IL-1 2 β -chain	150	AtLSAErvR	158
cat IL-12 β -chain	150	AtLSAEkvR	158
cow IL 12 β -chain	150	A1SAEkvn	158
Consensus HSP		AVLSA(d,e)(k,q)LR	
Consensus HLA		A(v,a)(l,h)(a,v)AEQLR	
Consensus IL-12 β -chain		A(v,l,t)LSAE(q,k,r)(l,v)R	
Overall Consensus		A(v,l,a,t)(l,h)(a,v)A(d,e)(k,q,r)(l,v)R	

FIG. 2

Amendments to the Drawings

The attached sheet of drawings includes amendments to Figure 2. This sheet, which includes Figure 2 replaces the substitute version of Figure 2, submitted in Applicants'

Amendment and Response to Office Action dated June 30, 2004. That version of Figure 2 contained a typographic error in the sequence of Hu Colligin 2.

Attachment:

1. Replacement Sheet
2. Annotated Sheet Showing Changes